WuXi Biologics (Cayman) Inc.

SEHK:2269 Rapporto sulle azioni

Cap. di mercato: HK$44.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

WuXi Biologics (Cayman) Salute del bilancio

Salute finanziaria criteri di controllo 5/6

WuXi Biologics (Cayman) ha un patrimonio netto totale di CN¥44.0B e un debito totale di CN¥2.1B, che porta il suo rapporto debito/patrimonio netto a 4.9%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥56.6B e CN¥12.6B. L'EBIT di WuXi Biologics (Cayman) è CN¥3.9B rendendo il suo rapporto di copertura degli interessi -64.8. Ha liquidità e investimenti a breve termine pari a CN¥11.2B.

Informazioni chiave

4.8%

Rapporto debito/patrimonio netto

CN¥2.16b

Debito

Indice di copertura degli interessi-18.3x
ContantiCN¥9.53b
Patrimonio nettoCN¥44.64b
Totale passivitàCN¥11.46b
Totale attivitàCN¥56.11b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08
Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Nov 26
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Nov 10
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Sep 26
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26
These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10
WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13
At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13
Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30
An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09
Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20
Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08
With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15
Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Aug 02
We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Jun 29
Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

May 16
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥21.2B ) di 2269 superano le sue passività a breve termine ( CN¥7.6B ).

Passività a lungo termine: Le attività a breve termine di 2269 ( CN¥21.2B ) superano le sue passività a lungo termine ( CN¥4.9B ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 2269 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 2269 è aumentato da 0% a 4.9% negli ultimi 5 anni.

Copertura del debito: Il debito di 2269 è ben coperto dal flusso di cassa operativo ( 217.4% ).

Copertura degli interessi: 2269 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.


Bilancio


Scoprire le aziende sane